Prevalence of Different Types of Cancer Among Patient in Najaf Province/ Iraq
DOI:
https://doi.org/10.46966/msjar.v2i2.22Keywords:
Tumors, Epidemiology Cancer, Types CancerAbstract
This study was carried out in Middle Euphrates cancer center, laboratories department, Al-Najaf holy city - Iraq; Iraqi patients have been recorded during period January 2018 until December 2018. This study has demonstrated that four different types of the following cancers: Breast cancer, brain cancer, lung cancer and Bladder cancer were registered in this study. Comparison was occured among each type of cancer was regarded in sex, age and number. The highest levels of cancer among all the other types were breast and lung cancer , the majority results in cancer epidemiology for this study, which showed 22% and 8 % respectively. While in other types, the result has showed 6%, 4.7%,for Bladder cancer, and braian cancer, respectively
References
Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu . Michael J. Thun. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66 7.
Iraqi Ministry of Health. Department of vital statistics 2008 report.390.
Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in Africa and opportunities for prevention. Cancer. 2012.
Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslathi E, Herschman H, Eng LF, Wikstrand CJ. J Neuropath Exp Neurol 40: 201-229, 1981.
Bigner DD, McLendon RE, Brunner JM (editors). Russel and Rubinstein's Pathology of Tumors of the Nervous System. 6th Ed. Arnold and Oxford University Press. London, Sydney, Auckland, 1998.
Lung Carcinoma:Tumors of the Lungs.Merck Manual Professional Edition.online edition. Retrieved 15th August 2007.
Non-small cell lung cancer Treatment-Patient Version(PDQ®).NCL.May 12,2015.retrieved 5 March 2016. Stewart,edited by Bemard W,Wild, Christopher P. World cancer report2014. Lyon:IARC Press pp.350-352.
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25(suppl 3): iii40-iii48.
Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010; 116(22): 5235-5242.
Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis. Cancer. 2009; 115(5): 988-996.
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25(suppl 3): iii40-iii48.
Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178(6): 2314-2330.
Clark PE, Agarwal N, Biagioli MC, et al.; National Comprehensive Can¬cer Network. Bladder cancer. J Natl Compr Canc Netw. 2013; 11(4): 446-475. 29. Witjes JA, Compérat E, Cowan NC, et al.; European Association of Urol¬ogy. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014; 65(4): 778-792.
Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. Published online ahead of print April 26, 2017.
American Cancer Society. (2013, October 24). How is breast cancer staged?
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correla¬tion of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014; 65(2): 350-357.
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published ocrrection appears in N Engl J Med. 2003; 349(19): 1880]. N Engl J Med. 2003; 349(9): 859-866.
Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Blad¬der Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Austra¬lian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrex¬ate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16): 2171-2177.
Maysoon K.A. AL-Hadrawi1, Noor Ibrahim2 et al, Indian Journal of Public Health Research & Development, July 2019, Vol.10, No. 7.
Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975– 2001, with a special feature regarding survival. Cancer2004;101:3–27.
Parkin,DM. Bray,F. Ferlay,J. Pisani,P. Global cancer statistic 2002. CA cancer J.Clin. 2005. 55,74-108.
Lynch,CF. Cohen,MB. Urinary system. Cancer. 1995. 75,316-329.
Golka,K. Wiese,A. Asseannato,G. Bolt,H. Occupational exposure and urological cancer. World.J.Urol. 2004. 21,382-398.
Morales,K. Ryan,L. Kuo,T. Wu,M. et al. Risk of internal cancer from arsenic in drinking water. Environ.Health perspect. 2000. 108,655-662.
Smith,A. Goycolea,M. Haque,R. Biggs,M. marked increase in bladder and lung cancer mortality in a region of north Chile due to arsenic in drinking water. Am.J.Epidemiol. 1998. 7,660-669h.
Navarro Silvera,SA. Rohan,TE. Trace elements and cancer risk. Review of the epidemiologic evidence. Cancer causes Control. 2007. 18,7-27.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Noor I. Abdul-Zahra, Zahraa K. Taiban
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
